Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $2.30
Volume
449.95 K
Value Traded
746.64 K
Short % Float
2.69%
+0.89%Week
+15.7%1 Month
-8.13%3 Month
-4.24%6 Month
-33.33%5 Year
-29.52%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
136.17 M
EPS (TTM)
-0.16
P/E Ratio
-
Ent. Value
172.35 M
Total Shares
120.46 M
Float Shares
64.36 M
Insiders
49.84%
Institutions
1.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TLSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Tiziana Life Sciences Ltd
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tiziana Life Sciences Ltd
534Total events
9Upcoming
75Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
●R&D DayForalumabPresentation
Community webinar hosted by Healey & AMG Center with Tiziana to discuss foralumab science
amyotrophic lateral sclerosis (ALS)source ↗
●Orphan Drug DesignationForalumabDesignation
Tiziana submits FDA Orphan Drug Designation request for intranasal foralumab in MSA
Multiple System Atrophy (MSA)source ↗
▲First Patient DosedForalumabTrial
First three participants dosed in Phase 2a BANYAN trial of intranasal foralumab in ALS
amyotrophic lateral sclerosis (ALS)source ↗
●Last Patient Last VisitForalumabTrial
Last patient completes last visit in Phase 2a INFORM-MS trial of intranasal foralumab
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)source ↗
▲Partnership / LicenseForalumabCorporate
Tiziana signs MOU with KAIMRC and Foundation for Neurologic Diseases for intranasal foralumab combination trial in RRMS
relapsing-remitting multiple sclerosis (RRMS)source ↗
◆Timing GuidanceForalumabPresentation
Database lock expected this week for Phase 2a INFORM-MS trial
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)source ↗
●Poster PresentationForalumabPresentation
Poster presentation on Phase 2a BANYAN trial at ALS Nexus 2026
ALSsource ↗
▲Biomarker DataForalumabClinical Data
Third MSA patient shows reduction in brain inflammation on PET imaging
Multiple System Atrophysource ↗
◆Topline ReadoutForalumabClinical Data
Topline data expected from Phase 2a trial of intranasal foralumab in na-SPMS
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)source ↗
◆Oral PresentationPresentation
Tiziana Life Sciences to present at Jefferies Global Healthcare Conference
◆Poster PresentationForalumabPresentation
Late-breaking poster accepted for presentation at 7th World Parkinson Congress
Multiple System Atrophysource ↗
▲Enrollment CompleteForalumabTrial
Patient enrollment completed in Phase 2a trial of intranasal foralumab in na-SPMS
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)source ↗
▲Full ResultsForalumabClinical Data
Updated clinical data from Expanded Access Program showing safety, EDSS stabilization, and fatigue improvement
non-active Secondary Progressive Multiple Sclerosissource ↗
▲Topline ReadoutForalumabClinical Data
Initial quantitative PET imaging results from first two MSA patients treated with intranasal foralumab show reduced brain inflammation
Multiple System Atrophysource ↗
▲Enrollment UpdateForalumabTrial
14 patients with na-SPMS dosed in open-label intermediate sized Expanded Access Program
Non-Active Secondary Progressive Multiple Sclerosissource ↗
●Trial InitiationForalumabTrial
Phase 2a trial in na-SPMS currently being studied
Non-Active Secondary Progressive Multiple Sclerosissource ↗
▲Preclinical PoCForalumabPreclinical
Positive preclinical data published in bioRxiv showing intranasal anti-CD3 antibody attenuates Long COVID neuroinflammation and improves cognitive function in mice
Long COVID neuroinflammationsource ↗
▲Preclinical PoCForalumabPreclinical
Nasal anti-CD3 improves cognition in aging model
age-related cognitive declinesource ↗
▲Poster PresentationForalumabPresentation
Late-breaking poster presented at Brigham and Women's Hospital showing biomarker data
non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse activity (PIRA)source ↗
▲PublicationForalumabPresentation
Peer-reviewed publication of open-label study results in Neurology Neuroimmunology & Neuroinflammation
non-active secondary progressive multiple sclerosissource ↗
▼Equity OfferingCorporate
Pricing of registered direct offering of 6,400,000 ordinary shares at $1.25 per share
◆Oral PresentationForalumabPresentation
Corporate presentation at 9th Annual Neuroscience Innovation Forum
non-active secondary progressive multiple sclerosissource ↗
◆Topline ReadoutForalumabClinical Data
Top-line data expected from Phase 2 randomized double-blind placebo-controlled trial
non-active secondary progressive multiple sclerosissource ↗
◆Topline ReadoutForalumabClinical Data
Top-line data expected from Phase 2a trial in na-SPMS
non-active secondary progressive multiple sclerosis (na-SPMS)source ↗
▲IND Safety ReportForalumabIND
Seventh annual DSUR submitted to FDA for intranasal foralumab
neuroinflammatory diseasessource ↗
▲First Patient DosedForalumabTrial
First patient expected to be dosed next week in Phase 2 Alzheimer's trial
early Alzheimer's diseasesource ↗
▲First Patient DosedForalumabTrial
First patient dosed in Phase 2 Alzheimer's trial
early Alzheimer's diseasesource ↗
▲Enrollment UpdateForalumabTrial
14 patients dosed in Expanded Access Program for na-SPMS
Non-Active Secondary Progressive Multiple Sclerosissource ↗
●Trial InitiationForalumabTrial
Phase 2a trial ongoing in na-SPMS
Non-Active Secondary Progressive Multiple Sclerosissource ↗
▼Equity OfferingCorporate
Withdrawal of proposed public offering of common shares due to market conditions
▲Enrollment CompleteForalumabTrial
Baseline assessments and screening completed for first participants in Phase 2 Alzheimer's trial
early Alzheimer's diseasesource ↗
◆Trial CompletionForalumabTrial
Blinded phase of Phase 2 trial expected to be completed
non-active secondary progressive multiple sclerosissource ↗
◆Trial CompletionForalumabTrial
Blinded portion of Phase 2 trial expected to complete by end of 2025
non-active Secondary Progressive Multiple Sclerosissource ↗
◆Topline ReadoutForalumabClinical Data
Topline data readout expected from Phase 2 trial of nasal foralumab in na-SPMS
non-active secondary progressive multiple sclerosissource ↗
▲Trial InitiationForalumabTrial
Phase 2 trial of intranasal foralumab in ALS accepted into Healey ALS MyMatch Program
amyotrophic lateral sclerosis (ALS)source ↗
◆Oral PresentationForalumabPresentation
Tiziana to present at Jefferies London Healthcare Conference
non-active secondary progressive multiple sclerosis, Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosissource ↗
◆Oral PresentationForalumabPresentation
Tiziana to present at BIO-Europe 2025
non-active secondary progressive multiple sclerosis, Multiple System Atrophy, early Alzheimer's disease, amyotrophic lateral sclerosissource ↗
▲First Patient DosedForalumabTrial
14 patients dosed in Expanded Access Program for na-SPMS
non-active secondary progressive multiple sclerosissource ↗
◆Trial InitiationForalumabTrial
Phase 2a trial in na-SPMS ongoing
non-active secondary progressive multiple sclerosissource ↗
●Quarterly UpdateCorporate
Interim financial results for six months ended June 30, 2025 filed
▼Equity OfferingCorporate
Raised additional $2m from sale of investment shares and ATM issuances post period end
●Poster PresentationForalumabPresentation
Poster presentation at ECTRIMS Congress on Phase 2a trial design
non-active secondary progressive multiple sclerosissource ↗
▲Enrollment UpdateForalumabTrial
10 patients dosed in Expanded Access Program
non-active secondary progressive multiple sclerosissource ↗
▲Preclinical PoCForalumabPreclinical
DoD grant awarded for intranasal anti-CD3 in acute SCI
traumatic spinal cord injurysource ↗
▲Trial InitiationForalumabTrial
Expanded Access Program dosed 10 patients
non-active secondary progressive multiple sclerosissource ↗
▲Enrollment CompleteForalumabTrial
10 patients dosed in Expanded Access Program for na-SPMS
Non-Active Secondary Progressive Multiple Sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How TLSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2019-09-01 | Milciclib (PHA-848125AC) | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$100M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
0.7x
rNPV / MCap
Top 37%
Micro Cap(rank 244 of 658)
Percentile Rank
Tiziana Life Sciences Ltd carries a moderate pipeline score (41/100), with $1.3B risk-adjusted pipeline value, led by Foralumab in Secondary Progressive Multiple Sclerosis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Foralumab Monoclonal antibodyNCT07688239 | ALS (Amyotrophic Lateral Sclerosis) | Phase 2 | NOT YET_RECRUITING | 44 | Nov 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every TLSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| foralumab Fast Track | Multiple System Atrophy | Phase 2 | 2026-07-31 | up to 34% reduction in standardized uptake value (SUV); 26% reduction in standardized uptake value ratio (SUVR); up to approximately 35% reduction in standardized uptake value (SUV); 24% reduction in standardized uptake value ratio (SUVR)Read More | Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal ForalumabRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Elrifi IvorOfficer (Chief Executive Officer) | Option | 1,050,000 5,843,684 held | $0.00 | 08/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TLSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TLSA for Q2 2026. | ||||
TLSA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TLSA ranks across every disease it competes in
Competitive Position is a premium feature
See how TLSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTLSA News
TLSA▲ +16.4%on this news
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
Tiziana Life Sciences has filed for Orphan Drug Designation with the FDA for intranasal foralumab, aimed at treating Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The company is currently conducting a Phase 2a clinical trial to evaluate the drug's effects on microglial activation and clinical outcomes. If granted, the designation could offer several regulatory benefits, including market exclusivity and tax credits.
Read more →TLSATiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
Tiziana Life Sciences has announced the dosing of the first three participants in the Phase 2a BANYAN clinical trial for intranasal foralumab, aimed at treating ALS. The trial, which is co-funded by the ALS Association, will evaluate the safety and tolerability of foralumab over a 12-week period. This milestone is seen as a significant step forward in ALS treatment research.
Read more →TLSATiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
Tiziana Life Sciences has announced the completion of the last patient visit in its Phase 2a INFORM-MS trial for intranasal foralumab, aimed at treating non-active Secondary Progressive Multiple Sclerosis. The trial involved 48 patients and evaluated the drug's safety and efficacy over a 12-week period. Topline data is expected to be released in October, with promising results from an Expanded Access Program indicating stabilization or improvement in patient outcomes.
Read more →TLSA▲ +26%on this newsshared move
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
Tiziana Life Sciences has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center to collaborate on a clinical trial for relapsing-remitting multiple sclerosis. The trial will evaluate the combination of Tiziana's intranasal foralumab and existing anti-CD20 therapy. This partnership aims to address unmet medical needs in neuroimmunology.
Read more →TLSATiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Tiziana Life Sciences announced a poster presentation on the Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026. The trial aims to evaluate the safety and efficacy of foralumab in ALS patients. The presentation will cover preclinical data, study design, and the role of regulatory T cells in ALS progression. The trial is currently in the operational startup phase.
Read more →TLSATiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Tiziana Life Sciences announced that CEO Ivor Elrifi purchased 667,000 shares at $1.00 each, increasing his total holdings to over 4.4 million shares. The company is developing intranasal foralumab, a monoclonal antibody that stimulates T regulatory cells, currently in clinical trials for non-active secondary progressive multiple sclerosis. The therapy shows potential for improved efficacy and safety compared to traditional intravenous methods.
Read more →TLSA▲ +6.2%on this news
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Tiziana Life Sciences announced positive results from its Phase 2 clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). The third patient treated showed reductions in brain inflammation, similar to previous patients. The findings support the drug's potential to modulate neuroinflammation, with plans for further evaluation in additional patients.
Read more →TLSA▼ -5.5%on this news
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Life Sciences announced that Executive Chairman Gabriele Cerrone has purchased 42,357 shares, increasing his total holdings to 44,814,587 shares, representing 34.93% of the company's capital. The company is advancing its lead candidate, intranasal foralumab, which is currently in clinical trials for non-active secondary progressive multiple sclerosis and has shown positive outcomes.
Read more →TLSATiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Tiziana Life Sciences has announced that the last patient has been dosed in its Phase 2a INFORM-MS trial, which evaluates intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis. The trial aims to assess safety and efficacy, with topline data expected in late Q3 or early Q4 of 2026. The results will be presented at an upcoming conference in Toronto.
Read more →TLSATiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Tiziana Life Sciences will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and CFO Keeren Shah will discuss recent clinical updates, including the progress of their lead candidate, intranasal foralumab, which is currently being studied in patients with non-active secondary progressive multiple sclerosis. The presentation will include a Q&A session with investors.
Read more →TLSA▼ -9.3%on this news
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Tiziana Life Sciences has announced the completion of patient enrollment for its Phase 2 placebo-controlled clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The INFORM-MS trial is significant as it marks the first placebo-controlled study of this monoclonal antibody, which targets neuroinflammation. The trial aims to measure the efficacy and safety of the treatment, with topline data expected in late Q3 2026. This milestone reflects both Tiziana’s efforts to address the limited treatment options available for na-SPMS and the company's commitment to advancing innovative therapies in neurodegenerative diseases.
Read more →TLSATiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences has announced positive clinical data for intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis. The updated data indicate that the treatment is well tolerated and shows promising trends in stabilizing disability and improving fatigue. The findings support the potential of foralumab as a novel therapy for this patient population.
Read more →TLSATiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
Tiziana Life Sciences has reported promising results from its Phase 2 clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Initial PET imaging showed up to a 35% reduction in inflammatory activity in critical brain regions. This marks the third indication demonstrating the drug's potential to reduce neuroinflammation, building on previous findings in other neurodegenerative conditions.
Read more →TLSATiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Tiziana Life Sciences announced positive preclinical data for its intranasal anti-CD3 antibody, foralumab, showing its ability to reduce neuroinflammation and enhance cognitive function in a Long COVID mouse model. The study, conducted by leading researchers, indicates that foralumab can effectively boost regulatory T cells in the brain and improve memory. These findings support its potential as a treatment for cognitive impairments associated with Long COVID.
Read more →TLSA▲ +12.2%on this newsshared move
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a study of intranasal foralumab for Multiple System Atrophy has been accepted for presentation at the 7th World Parkinson Congress. The study aims to evaluate the drug's potential to reduce neuroinflammation and microglial activation in MSA. The trial is currently enrolling participants and highlights a novel approach to treating this challenging condition.
Read more →TLSA▲ +6.8%on this news
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
Tiziana Life Sciences announced promising preclinical data for its nasal anti-CD3 monoclonal antibody, foralumab, indicating its potential to improve cognitive function associated with aging. The study revealed that nasal anti-CD3 reduces neuroinflammation and enhances neurogenesis in the hippocampus. Tiziana is advancing clinical trials for foralumab in various neurodegenerative conditions.
Read more →TLSATiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
Tiziana Life Sciences announced positive biomarker data for its lead candidate, nasal foralumab, in treating non-active secondary progressive multiple sclerosis (na-SPMS). The data indicates that foralumab downregulates CSF inflammation and correlates with reduced microglial activation on PET scans. This supports the ongoing Phase 2 program and highlights the potential of foralumab in neuroinflammatory conditions.
Read more →About Tiziana Life Sciences Ltd
BIOPHARMAWATCH ELITE PLUS
Trade the next TLSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime